SHPMF (Shanghai Pharmaceuticals Holding Co) Risk Assessment


SHPMF Shanghai Pharmaceuticals Holding Co Ltd SHPMF
73 GF Score
Price $1.46
GF Value $1.81
! 4 Warning Signs
View Full Analysis

What is Shanghai Pharmaceuticals Holding Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shanghai Pharmaceuticals Holding Co is: No Data: Cannot be evaluated.

Shanghai Pharmaceuticals Holding Co  (OTCPK:SHPMF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shanghai Pharmaceuticals Holding Co Risk Assessment Related Terms

SHPMF vs MCK, CAH, COR: Risk Assessment Comparison

For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Pharmaceuticals Holding Co Risk Assessment vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's Risk Assessment falls into.


SHPMF
73GF Score
Shanghai Pharmaceuticals Holding Co Ltd SHPMF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued. The current stock price of $1.46 is trading 19.3% below its estimated GF Value™ of $1.81.

Key valuation signals for SHPMF:

  • Risk Assessment:
  • GF Value™: $1.81 vs. price of $1.46 (19.3% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Pharmaceuticals Holding Co Business Description

Address No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
73GF Score

Get the complete analysis for SHPMF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.46
Price
$1.81
GF Value